Prior treatment with enzalutamide or abiraterone acetate for > 14 days prior to enrollment and completion of baseline tests.
Receipt of chemotherapy for prostate or other cancer within the past 12 months with residual cognitive deficits, or receipt of chemotherapy for mCRPC. Patients/physicians planning treatment with chemotherapy during the 12 month period of the investigation are also ineligible.
History of cognitive impairment or dysfunction, including a history of dementia, Alzheimer's disease, stroke with residual cognitive deficits, cognitive dysfunction related to alcohol or substance abuse, or cognitive dysfunction related to prior treatment for any cancer.
Patients with a seizure history, history of recurrent falls, or known brain metastases are excluded from this clinical trial because of their poor prognosis and because of their heightened risk of seizure or progressive cognitive and/or neurologic dysfunction that would confound the evaluation.
Uncontrolled intercurrent illness including, but not limited to, uncontrolled diabetes, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III and IV heart failure), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations/substance abuse that would limit compliance with study requirements.
Patients with a "currently active" second malignancy other than non-melanoma skin cancers are not eligible. Patients are not considered to have a "currently active" malignancy if they have completed all therapy and are now considered without evidence of disease for 1 year. Patients with cognitive dysfunction related to treatment of another malignancy, including a history of "chemo-brain", are ineligible.
Patients taking psychotropic medications or illicit drugs that may alter cognition, concentration, or behavior. Appropriate treatment by a licensed provider with medications for depression or anxiety, including but not limited to SSRIs, SNRIs, and standard dose benzodiazepines at a stable dose, is permitted

NCT03016741_exc_T1
Drug
enzalutamide
NCT03016741_exc_T2
Drug
abiraterone acetate
NCT03016741_exc_T3
Multiplier
for > 14 days
NCT03016741_exc_T4
Temporal
prior to enrollment
NCT03016741_exc_T5
Reference_point
enrollment
NCT03016741_exc_T6
Procedure
treatment
NCT03016741_exc_T7
Scope
enzalutamide or abiraterone acetate
NCT03016741_exc_T8
Procedure
chemotherapy
NCT03016741_exc_T9
Condition
rostate ancer
NCT03016741_exc_T10
Qualifier
other
NCT03016741_exc_T11
Condition
cancer
NCT03016741_exc_T12
Scope
prostate or other cancer
NCT03016741_exc_T13
Temporal
within the past 12 months
NCT03016741_exc_T14
Condition
residual cognitive deficits
NCT03016741_exc_T15
Procedure
chemotherapy
NCT03016741_exc_T16
Condition
mCRPC
NCT03016741_exc_T18
Condition
cognitive impairment
NCT03016741_exc_T19
Condition
gnitive i sfunction,
NCT03016741_exc_T20
Condition
dementia
NCT03016741_exc_T21
Condition
Alzheimer's disease
NCT03016741_exc_T22
Condition
stroke
NCT03016741_exc_T23
Condition
residual cognitive deficits
NCT03016741_exc_T24
Condition
cognitive dysfunction
NCT03016741_exc_T25
Condition
substance abuse
NCT03016741_exc_T26
Condition
cohol o use,
NCT03016741_exc_T27
Scope
cognitive impairment or dysfunction
NCT03016741_exc_T28
Condition
cognitive dysfunction
NCT03016741_exc_T29
Procedure
treatment
NCT03016741_exc_T30
Temporal
prior
NCT03016741_exc_T31
Condition
cancer
NCT03016741_exc_T32
Qualifier
any
NCT03016741_exc_T33
Scope
dementia, Alzheimer's disease, stroke with residual cognitive deficits, cognitive dysfunction related to alcohol or substance abuse, or cognitive dysfunction related to prior treatment for any cancer
NCT03016741_exc_T34
Condition
seizure
NCT03016741_exc_T35
Condition
recurrent falls
NCT03016741_exc_T36
Condition
brain metastases
NCT03016741_exc_T37
Observation
history
NCT03016741_exc_T38
Observation
history of
NCT03016741_exc_T39
Condition
intercurrent illness
NCT03016741_exc_T40
Qualifier
Uncontrolled
NCT03016741_exc_T41
Qualifier
uncontrolled
NCT03016741_exc_T42
Condition
diabetes
NCT03016741_exc_T43
Temporal
ongoing
NCT03016741_exc_T44
Qualifier
active
NCT03016741_exc_T45
Condition
infection
NCT03016741_exc_T46
Scope
ongoing or active
NCT03016741_exc_T47
Qualifier
symptomatic
NCT03016741_exc_T48
Condition
congestive heart failure
NCT03016741_exc_T49
Measurement
New York Heart Association
NCT03016741_exc_T50
Value
Class III and IV
NCT03016741_exc_T51
Condition
heart failure
NCT03016741_exc_T52
Scope
New York Heart Association Class III and IV heart failure
NCT03016741_exc_T53
Scope
symptomatic congestive heart failure
NCT03016741_exc_T54
Condition
unstable angina pectoris
NCT03016741_exc_T55
Condition
cardiac arrhythmia
NCT03016741_exc_T56
Condition
psychiatric illness
NCT03016741_exc_T57
Condition
social situations
NCT03016741_exc_T58
Condition
substance abuse
NCT03016741_exc_T59
Scope
uncontrolled diabetes, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III and IV heart failure), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations/substance abuse
NCT03016741_exc_T60
Scope
Uncontrolled intercurrent illness
NCT03016741_exc_T61
Multiplier
second
NCT03016741_exc_T62
Condition
malignancy
NCT03016741_exc_T63
Qualifier
currently active
NCT03016741_exc_T64
Condition
non-melanoma skin cancers
NCT03016741_exc_T65
Negation
other than
NCT03016741_exc_T66
Condition
cognitive dysfunction
NCT03016741_exc_T67
Procedure
treatment
NCT03016741_exc_T68
Qualifier
another
NCT03016741_exc_T69
Condition
malignancy
NCT03016741_exc_T70
Drug
psychotropic medications
NCT03016741_exc_T71
Drug
illicit drugs
NCT03016741_exc_T72
Condition
alter cognition
NCT03016741_exc_T73
Condition
cogni tration, or b
NCT03016741_exc_T74
Condition
cogni or. Appr
NCT03016741_exc_T75
Scope
psychotropic medications or illicit drugs
NCT03016741_exc_T76
Scope
alter cognition, concentration, or behavior